Precious metals are not merely ornaments; they are also important components of pharmaceuticals, like the antitumor drug ...

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...

Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the ...

Precious metals are not merely ornaments; they are also important components of pharmaceuticals, like the antitumor drug cisplatin. Recently, the search for alternatives with improved activity has ...

Researchers from Tianjin Accendatech Technology Co. Ltd. and collaborators have reported the discovery of a series of novel fluorine-containing parthenolide derivatives designed for use as antitumoral ...

Antibody-drug conjugates, a well-established antitumor strategy, are used for targeted delivery of cytotoxic drugs through antibodies. As cancer research progresses, other technologies with different ...

A phase I–II trial has demonstrated substantial antitumor activity for MDV3100 in patients with castration-resistant disease, including those who have previously received chemotherapy.

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

Details of the oral presentation, entitled “Farnesyl transferase inhibitor KO-2806 enhances the antitumor activity of cabozantinib in ccRCC tumors that progress on anti-VEGFR agents” (oral 6370), are ...